Home>>Signaling Pathways>> Neuroscience>> Pain Research>>N-Arachidonoyl Dopamine

N-Arachidonoyl Dopamine (Synonyms: NADA)

Catalog No.GC18506

N-Arachidonoyl Dopamine is a potent and selective endogenous CB1 receptor agonist with a Ki of 250 nM.

Products are for research use only. Not for human use. We do not sell to patients.

N-Arachidonoyl Dopamine Chemical Structure

Cas No.: 199875-69-9

Size Price Stock Qty
5mg
$75.00
In stock
10mg
$138.00
In stock
50mg
$578.00
In stock
100mg
$907.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
Several different arachidonoyl amino acids, including N-arachidonoyl dopamine (NADA), have been isolated and characterized from bovine brain. NADA is the amide of the neurotransmitter dopamine and arachidonic acid. NADA is a CB1-selective agonist, inducing the typical tetrad of hypothermia, analgesia, catalepsy, and hypomotility in rats which exceeds that of anandamide (AEA). NADA is a full agonist at the vanilloid receptor 1, but is inactive on the dopaminergic D1 and D2 receptors. NADA is also a potent inhibitor (IC50 = 0.25 uM) of the proliferation of MCF-7 breast carcinoma cells. Recent reports of NADA’s endothelium-dependent vasodilation indicate that some of its cannabinergic activities antagonized by SR141716A may be non-CB1/CB2 dependent.

Reviews

Review for N-Arachidonoyl Dopamine

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for N-Arachidonoyl Dopamine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.